☆ 3.8 Editorial Material

EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)-A Podcast Discussion Between Patients and Oncologists

ONCOLOGY AND THERAPY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Katie Chon et al.

Summary: The FDA granted accelerated approval for amivantamab, a bispecific antibody targeting EGFR and mesenchymal-epithelial transition receptor, for the treatment of NSCLC patients with EGFR exon 20 insertion mutations. The approval was based on a clinical trial demonstrating a 40% ORR and a median response duration of 11.1 months.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Oncology

Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer

Ebaa Al-Obeidi et al.

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2023)

Add to Collection

Article Oncology

Comparison of efficacy and safety of second- and third-generation TKIs for non-small-cell lung cancer with uncommon EGFR mutations

Yue Hao et al.

Summary: The efficacy and safety of second- and third-generation TKIs in NSCLC patients with uncommon EGFR mutations were compared, and no significant difference was found. They can be used for the treatment of patients with these mutations.

CANCER MEDICINE (2023)

Add to Collection

Article Oncology

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations

L. C. Villaruz et al.

Summary: This study investigates the efficacy and safety of osimertinib in patients with specific EGFR mutations in advanced non-small-cell lung cancer. The results suggest that osimertinib has activity in patients with these uncommon EGFR mutations and may have potential clinical utility.

ESMO OPEN (2023)

Add to Collection

Article Oncology

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

A. Passaro et al.

Summary: The European Society for Medical Oncology (ESMO) conducted a virtual consensus-building process in 2021 to discuss the management of EGFR-mutant non-small-cell lung cancer. The experts developed recommendations on various topics, including tissue and biomarkers analyses, early and locally advanced disease, metastatic disease, clinical trial design, patient's perspective, and miscellaneous.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network

Nicholas J. Robert et al.

Summary: The MYLUNG consortium study examined real-world biomarker testing rates and turnaround times within a community cancer network, finding that while most patients received at least one biomarker test, less than 50% received all five tests.

LUNG CANCER (2022)

Add to Collection

Article Oncology

Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer

Helen Sadik et al.

Summary: Many patients with cancer are unable to receive the most effective personalized treatments due to challenges in integrating predictive biomarker testing into clinical care. Clinical practice gaps, such as operational inefficiencies and inappropriate testing result usage, contribute to the loss of patients along the precision oncology pathway. This study analyzed the impact of these gaps on the treatment of advanced non-small-cell lung cancer (aNSCLC), revealing that a significant percentage of eligible patients do not benefit from precision oncology therapies.

JCO PRECISION ONCOLOGY (2022)

Add to Collection

Article Oncology

Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)

Jason S. Agulnik et al.

Summary: This study demonstrates the utility of plasma ctDNA as a noninvasive biomarker for detecting resistance mutations, monitoring treatment response and tumor progression in lung cancer patients. The detection of original mutations at baseline predicts poor progression-free survival and overall survival. The clearance and re-emergence of driver mutations during TKI treatment effectively identifies disease progression.

CURRENT ONCOLOGY (2022)

Add to Collection

Article Oncology

Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs

Oscar Arrieta et al.

Summary: The study found that the detection of plasma EGFRm at the time of tumor response evaluation in NSCLC patients receiving EGFR-TKIs is associated with poor clinical outcomes.

CANCER BIOMARKERS (2021)

Add to Collection

Article Medicine, General & Internal

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

S. S. Ramalingam et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

Jang Ho Cho et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

Yi-Long Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Fabrice Barlesi et al.

LANCET (2016)

Add to Collection

Article

The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

Yue-Lun Zhang et al.

Oncotarget (2016)

Add to Collection

Review Oncology

Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis

Feng-Che Kuan et al.

BRITISH JOURNAL OF CANCER (2015)

Add to Collection

Review Oncology

Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

Chee Khoon Lee et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)

Add to Collection

Article Oncology

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial

Mark A. Socinski et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Article Oncology

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

H Shigematsu et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.